Liver cancer screening and health technology assessment in China_Chinese Journal of Evidence-Based Medicine

Authors：

SHI Jufang ¹ , ZHAO Kun ² ,  QU Chunfeng ³ , HAN Youli ⁴ , ZHAO Jianjun ⁵ ,  DAI Min ¹

1. Office of Cancer Screening, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R.China;
2. Division of Health Policy Evaluation and Technology Assessment, China National Health Development Research Center, National Health Commission, Beijing, 100191, P.R.China;
3. Department of Immunology/State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R.China;
4. School of Health Management and Education, Capital Medical University, Beijing, 100069, P.R.China;
5. Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R.China;

Corresponding author：

QU Chunfeng, Email: quchf@cicams.ac.cn; DAI Min, Email: daimin2002@hotmail.com

Keywords：

Liver cancer; Burden of disease; Screening; Health technology assessment

DOI：

10.7507/1672-2531.201802022

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Health technology assessment (HTA) is becoming more and more popular recently. For populations in China that share at least half of the global disease burden of liver cancer, it is extremely vital to give rise to an efficient secondary prevention strategy. The China central government launched liver cancer screening program in rural areas in 2005, and then extended to populations in urban in 2012. The studies of health technology assessment of liver cancer screening are based on available evidence, from an HTA perspective, aims to evaluate performance of liver screening, economic burden and cost-effectiveness and some other issues, in order to raise suggestions for possible directions in research and public health program related to liver cancer screening in China.

Citation： SHI Jufang, ZHAO Kun, QU Chunfeng, HAN Youli, ZHAO Jianjun, DAI Min. Liver cancer screening and health technology assessment in China. Chinese Journal of Evidence-Based Medicine, 2018, 18(5): 397-400. doi: 10.7507/1672-2531.201802022 Copy

1.	赵琨, 隋宾艳, 郭武栋, 等. 卫生技术评估的国际经验及启示. 中国卫生经济, 2012, 31(2): 87-89.
2.	International Cancer Screening Network. Comparative Data by Screening Program. Available at: https:// healthcaredelivery.cancer.gov/icsn/.
3.	Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No.11. Available at: http://globocan.iarc.fr.
4.	Arguedas MR. Screening for hepatocellular carcinoma: why, when, how? Curr Gastroenterol Rep, 2003, 5(1): 57-62.
5.	Hernaez R, Kanwal F, El-Serag HB. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology, 2018, [Epub ahead of print].
6.	de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology, 2015, 62(4): 1190-1200.
7.	Zhang Y, Ren JS, Shi JF, et al. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer, 2015, 15: 94.
8.	Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis, 2013, 34(8): 1800-1805.
9.	Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med, 2014, 11(12): e1001774.
10.	El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, 142(6): 1264-1273.
11.	卫生部疾病预防控制司, 癌症早诊早治项目专家委员会. 癌症早诊早治项目技术方案(2011 年版). 北京: 人民卫生出版社, 2011.
12.	代敏, 石菊芳, 李霓. 中国城市癌症早诊早治项目设计及预期目标. 中华预防医学杂志, 2013, 47(2): 179-182.
13.	石菊芳, 代敏. 中国癌症筛查的卫生经济学评价. 中华预防医学杂志, 2017, 51(2): 107-111.
14.	Shi JF, Huang HY, Guo LW, et al. Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey. Lancet, 2016, 388(Suppl 1): S29.
15.	Huang HY, Shi JF, Guo LW, et al. Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study. Lancet, 2016, 388(Suppl 1): S10.
16.	Shi JF, Mao AY, Sun ZX, et al. Sustainability of cancer screening in China: a multicenter assessment from the perspective of service suppliers and demanders. Lancet, 2017, 390(Suppl 1): S95.
17.	Wang L, Shi JF, Wu N, et al. Trends on clinical characteristics and medical service use of lung cancer in China 2005-14: a multicentre retrospective survey. Lancet, 2017, 390(Suppl 1): S25.
18.	石菊芳, 张玥, 曲春枫, 等. 以伤残调整生命年为指标的中国人群癌症疾病负担现状. 中华预防医学杂志, 2015, 49(4): 365-369.
19.	冉建朝, 王乐, 张玥, 等. 中国人群肝癌所致 DALY 疾病负担: 1990 ~ 2016 年长期分析及预测. 中国循证医学杂志, 2018, 18(5): 401-409.
20.	黄佳文, 朱娟, 黄慧瑶, 等. 中国肝癌及相关疾病状态健康效用值及失能权重研究的系统评价. 中国循证医学杂志, 2018, 18(5): 410-417.
21.	严永峰, 王宇婷, 朱陈, 等. 肝癌筛查技术准确性的 Meta 分析. 中国循证医学杂志, 2018, 18(5): in press.
22.	樊春笋, 朱建, 王宇婷, 等. 基于启东的中国农村原发性肝癌发病危险因素及高危人群筛选分析的队列研究. 中国循证医学杂志, 2018, 18(5): 418-427.
23.	张业繁, 郭兰伟, 白方舟, 等. 中国肝癌患者 2002 ~ 2011 年日均医疗费用趋势分析:多中心回顾性调查. 中国循证医学杂志, 2018, 18(5): 434-441.
24.	白方舟, 王乐, 王宇婷, 等. 中国肝癌筛查卫生经济学研究的系统评价. 中国循证医学杂志, 2018, 18(5): 442-449.
25.	赵琨. 卫生技术评估与卫生政策评价-理论与方法篇. 北京: 人民卫生出版社, 2016: 3-4.
26.	代敏, 石菊芳, 毛阿燕. 我国城市地区癌症筛查供需方角度的可持续评估. 中华流行病学杂志, 2018, 39(2): 139-141.
27.	Chen WQ, Sun KX, Zheng RS, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res, 2018, 30(1): 1.
28.	Li Y, Shi J, Yu S, et al. Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospital-based multicenter retrospective clinical epidemiological study in China, 2005-2014. Cancer Med, 2017, 6(10): 2440-2452.

1. 赵琨, 隋宾艳, 郭武栋, 等. 卫生技术评估的国际经验及启示. 中国卫生经济, 2012, 31(2): 87-89.
2. International Cancer Screening Network. Comparative Data by Screening Program. Available at: https:// healthcaredelivery.cancer.gov/icsn/.
3. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No.11. Available at: http://globocan.iarc.fr.
4. Arguedas MR. Screening for hepatocellular carcinoma: why, when, how? Curr Gastroenterol Rep, 2003, 5(1): 57-62.
5. Hernaez R, Kanwal F, El-Serag HB. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology, 2018, [Epub ahead of print].
6. de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology, 2015, 62(4): 1190-1200.
7. Zhang Y, Ren JS, Shi JF, et al. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer, 2015, 15: 94.
8. Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis, 2013, 34(8): 1800-1805.
9. Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med, 2014, 11(12): e1001774.
10. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 2012, 142(6): 1264-1273.
11. 卫生部疾病预防控制司, 癌症早诊早治项目专家委员会. 癌症早诊早治项目技术方案(2011 年版). 北京: 人民卫生出版社, 2011.
12. 代敏, 石菊芳, 李霓. 中国城市癌症早诊早治项目设计及预期目标. 中华预防医学杂志, 2013, 47(2): 179-182.
13. 石菊芳, 代敏. 中国癌症筛查的卫生经济学评价. 中华预防医学杂志, 2017, 51(2): 107-111.
14. Shi JF, Huang HY, Guo LW, et al. Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey. Lancet, 2016, 388(Suppl 1): S29.
15. Huang HY, Shi JF, Guo LW, et al. Expenditure and financial burden for common cancers in China: a hospital-based multicentre cross-sectional study. Lancet, 2016, 388(Suppl 1): S10.
16. Shi JF, Mao AY, Sun ZX, et al. Sustainability of cancer screening in China: a multicenter assessment from the perspective of service suppliers and demanders. Lancet, 2017, 390(Suppl 1): S95.
17. Wang L, Shi JF, Wu N, et al. Trends on clinical characteristics and medical service use of lung cancer in China 2005-14: a multicentre retrospective survey. Lancet, 2017, 390(Suppl 1): S25.
18. 石菊芳, 张玥, 曲春枫, 等. 以伤残调整生命年为指标的中国人群癌症疾病负担现状. 中华预防医学杂志, 2015, 49(4): 365-369.
19. 冉建朝, 王乐, 张玥, 等. 中国人群肝癌所致 DALY 疾病负担: 1990 ~ 2016 年长期分析及预测. 中国循证医学杂志, 2018, 18(5): 401-409.
20. 黄佳文, 朱娟, 黄慧瑶, 等. 中国肝癌及相关疾病状态健康效用值及失能权重研究的系统评价. 中国循证医学杂志, 2018, 18(5): 410-417.
21. 严永峰, 王宇婷, 朱陈, 等. 肝癌筛查技术准确性的 Meta 分析. 中国循证医学杂志, 2018, 18(5): in press.
22. 樊春笋, 朱建, 王宇婷, 等. 基于启东的中国农村原发性肝癌发病危险因素及高危人群筛选分析的队列研究. 中国循证医学杂志, 2018, 18(5): 418-427.
23. 张业繁, 郭兰伟, 白方舟, 等. 中国肝癌患者 2002 ~ 2011 年日均医疗费用趋势分析:多中心回顾性调查. 中国循证医学杂志, 2018, 18(5): 434-441.
24. 白方舟, 王乐, 王宇婷, 等. 中国肝癌筛查卫生经济学研究的系统评价. 中国循证医学杂志, 2018, 18(5): 442-449.
25. 赵琨. 卫生技术评估与卫生政策评价-理论与方法篇. 北京: 人民卫生出版社, 2016: 3-4.
26. 代敏, 石菊芳, 毛阿燕. 我国城市地区癌症筛查供需方角度的可持续评估. 中华流行病学杂志, 2018, 39(2): 139-141.
27. Chen WQ, Sun KX, Zheng RS, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res, 2018, 30(1): 1.
28. Li Y, Shi J, Yu S, et al. Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospital-based multicenter retrospective clinical epidemiological study in China, 2005-2014. Cancer Med, 2017, 6(10): 2440-2452.

Next Article
Disability adjusted life years for liver cancer in China: trend analysis from 1990 to 2016 and future prediction

Chinese Journal of Evidence-Based Medicine

Liver cancer screening and health technology assessment in China

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content